Nuvation Bio Inc.
NUVBNYSETrackedMarket Data VerifiedHealth CarePharmaceuticals
- Coverage
- Coverage universe Identity published; no third-party ESG observation yet.
- ESG profile reviewed
- Last editorial update to this profile.
- Quote
- Last verified closeObservation time is shown beside the price.
- Methodology
- How we rateProvider ratings are shown separately, never blended.
Market overview
Down−USD 0.42 (−7.55%) Day change
The market is closed. This is the last verified closing quote, not an intraday price.
- Open
- USD 5.66
- Previous close
- USD 5.56
- Day high
- USD 5.66
- Day low
- USD 5.03
- Volume
- 14,820,420
- Market cap
- USD 1,804,773,376
View Chart Data
| Date and time | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| USD 3.75 | USD 3.85 | USD 3.66 | USD 3.71 | 7,086,700 | |
| USD 3.55 | USD 3.62 | USD 3.36 | USD 3.41 | 5,843,100 | |
| USD 4.99 | USD 7.35 | USD 4.94 | USD 7.15 | 59,110,300 | |
| USD 8.30 | USD 8.56 | USD 8.11 | USD 8.31 | 7,244,900 | |
| USD 9.02 | USD 9.53 | USD 9.01 | USD 9.44 | 8,225,700 | |
| USD 9.52 | USD 9.75 | USD 9.40 | USD 9.54 | 5,691,700 | |
| USD 8.50 | USD 9.10 | USD 8.50 | USD 8.84 | 6,129,300 | |
| USD 5.92 | USD 6.00 | USD 5.55 | USD 5.59 | 6,021,300 | |
| USD 5.72 | USD 5.92 | USD 5.31 | USD 5.64 | 4,703,400 | |
| USD 5.76 | USD 5.80 | USD 5.52 | USD 5.56 | 3,348,900 | |
| USD 4.46 | USD 4.50 | USD 4.32 | USD 4.37 | 3,560,200 | |
| USD 4.37 | USD 4.59 | USD 4.21 | USD 4.25 | 4,154,700 | |
| USD 4.50 | USD 4.75 | USD 4.50 | USD 4.70 | 1,957,500 | |
| USD 4.59 | USD 4.62 | USD 4.46 | USD 4.56 | 4,564,200 | |
| USD 4.84 | USD 4.86 | USD 4.70 | USD 4.78 | 5,395,100 | |
| USD 4.72 | USD 4.78 | USD 4.62 | USD 4.78 | 4,201,600 | |
| USD 5.04 | USD 5.16 | USD 4.87 | USD 5.14 | 4,183,900 | |
| USD 5.68 | USD 5.91 | USD 5.33 | USD 5.42 | 8,356,900 | |
| USD 5.55 | USD 5.85 | USD 5.34 | USD 5.80 | 3,605,400 | |
| USD 6.36 | USD 6.42 | USD 6.07 | USD 6.16 | 5,569,200 | |
| USD 6.13 | USD 6.60 | USD 6.13 | USD 6.48 | 5,055,100 | |
| USD 6.60 | USD 6.95 | USD 6.58 | USD 6.64 | 4,843,600 | |
| USD 5.96 | USD 6.16 | USD 5.92 | USD 6.07 | 5,738,500 | |
| USD 5.66 | USD 5.66 | USD 5.03 | USD 5.14 | 14,825,000 |
Company Profile & Business Model Overview
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.
Sustainability Strengths & Catalysts (Pros)
- Focused R&D on severe diseases: Nuvation Bio concentrates resources on oncology therapeutics for unmet medical needs, which can deliver high patient and societal value if clinical programs succeed.
- Clinical governance and external reporting: As a publicly listed company filing SEC disclosures (including a 2026 10-K/8-K), Nuvation provides regulatory financial and clinical program reporting that supports investor transparency.
- Global operational footprint: Presence in multiple U.S. hubs and Shanghai supports access to diverse research talent and clinical trial sites, which can improve trial diversity and operational resilience.
Material Risks & Governance Concerns (Cons)
- High clinical and commercial risk inherent to biotech: As a clinical-stage company with no marketed products, Nuvation faces elevated financial and pipeline risk, including trial failures and capital raises that can dilute shareholders and impact long-ter
- Limited disclosures on environmental and social management: Public filings and profiles focus on corporate and clinical matters with limited, specific reporting on environmental impacts, greenhouse gas emissions, workforce diversity metrics, or formal ESG
Related ESG Peer Equities
Companies in Health Care evaluated across carbon intensity, social metrics, and board governance.
ESG & Sustainability Rating Breakdown
Synthesized multi-provider rating across Environmental, Social, and Corporate Governance dimensions.
Audited Methodology
Formal published scorecards from MSCI ESG Research and Sustainalytics are not currently available for this ticker. The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.
Data integrity and methodology
MSCI and Sustainalytics ratings are shown separately with their own observation dates; they are not blended into one score, and providers can disagree. Market quotes are delayed or last-close values, and every snapshot states its source and observation time. Read the full rating methodology.
Financial & Valuation Fundamentals
Core balance sheet and equity valuation metrics sourced from corporate filings.
Audited Financials
Related ESG Financial Tools & Modeling
ESG Investment Growth Calculator
Project compound future portfolio values versus traditional index benchmarks.
Launch Tool →
Portfolio Carbon Footprint Calculator
Translate your investment capital into financed greenhouse gas emissions.
Launch Tool →
Green Mortgage Calculator
Calculate interest rate discounts on energy-efficient certified homes.
Launch Tool →
Featured Sustainable Investment Research & Guides
Top 12 Impact Investing Apps & Platforms (Reviewed)
Comprehensive review of the best ESG micro-investing and direct indexing apps.
Biblically Responsible Investing (BRI): Top Stocks & Funds
Faith-based screening criteria, ESG alignment, and values-based portfolio strategies.
Top Desalination & Clean Water Infrastructure Stocks
Invest in global clean water purification, reverse osmosis, and municipal utilities.
Best Certified B-Corp Banks & Sustainable Banking
How to align your everyday cash reserves with social and climate impact standards.
Frequently Asked Questions
Direct answers on sustainability scores, risk methodologies, and peer rankings.
What is Nuvation Bio Inc. (NUVB)'s ESG rating and sustainability score?
Formal published scorecards from MSCI and Sustainalytics are under ongoing review for Nuvation Bio Inc. (NUVB). The Impact Investor tracks corporate sustainability disclosures, SEC 10-K filings, and governance releases.
Is Nuvation Bio Inc. considered an ESG leader or laggard in Health Care?
Independent benchmark status for Nuvation Bio Inc. is evaluated relative to Health Care peers once third-party coverage publishes official methodology scores.
What are the main ESG risks and controversies for Nuvation Bio Inc.?
Key material risks for Nuvation Bio Inc. include: High clinical and commercial risk inherent to biotech: As a clinical-stage company with no marketed products, Nuvation faces elevated financial and pipeline risk, including trial failures and capital raises that can dilute shareholders and impact long-ter; Limited disclosures on environmental and social management: Public filings and profiles focus on corporate and clinical matters with limited, specific reporting on environmental impacts, greenhouse gas emissions, workforce diversity metrics, or formal ESG. Investors should evaluate whether corporate mitigation plans adequately address these vulnerabilities.
How does The Impact Investor evaluate ESG stock profiles?
The Impact Investor presents audited third-party ratings from MSCI and Sustainalytics alongside delayed market data and financial fundamentals. We do not blend ratings into proprietary black-box scores, and ratings are never modified by advertising or affiliate relationships.